China Pharma Financials
This page shows China Pharma (CPHI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 cash improvement came from asset unwind and minimal reinvestment while the core business still sold below cost for another year.
FY2025 paired a$3.2M net loss with$89K of free cash flow, which usually means non-cash charges or working-capital release are doing the heavy lifting. That is what the supporting lines show: depreciation and amortization were about$1.5M while gross margin stayed at-3.2% , so cash improved because the company consumed fewer assets, not because each sale became profitable.
Book leverage eased from 1.2x in FY2023 to 0.4x in FY2025, so the balance sheet looks less burdened by liabilities in aggregate. But near-term liquidity tightened: the current ratio fell to 0.3x and cash finished at
Revenue is down by more than half versus FY2021, and SG&A consumed
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of China Pharma's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
China Pharma scores -0.86, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($23.1M) relative to total liabilities ($8.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
China Pharma passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, China Pharma generates $-0.05 in operating cash flow ($148K OCF vs -$3.2M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
China Pharma earns $-118.8 in operating income for every $1 of interest expense (-$3.2M vs $27K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
China Pharma generated $4.1M in revenue in fiscal year 2025. This represents a decrease of 8.5% from the prior year.
China Pharma's EBITDA was -$1.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 11.9% from the prior year.
China Pharma reported -$3.2M in net income in fiscal year 2025. This represents an increase of 32.7% from the prior year.
Cash & Balance Sheet
China Pharma generated $89K in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 120.0% from the prior year.
China Pharma held $345K in cash against $0 in long-term debt as of fiscal year 2025.
China Pharma had 16M shares outstanding in fiscal year 2025.
Margins & Returns
China Pharma's gross margin was -3.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 40.7 percentage points from the prior year.
China Pharma's operating margin was -78.2% in fiscal year 2025, reflecting core business profitability. This is up 23.2 percentage points from the prior year.
China Pharma's net profit margin was -76.9% in fiscal year 2025, showing the share of revenue converted to profit. This is up 27.7 percentage points from the prior year.
China Pharma's ROE was -14.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 47.1 percentage points from the prior year.
Capital Allocation
China Pharma invested $281K in research and development in fiscal year 2025. This represents a decrease of 1.1% from the prior year.
China Pharma invested $59K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 54.4% from the prior year.
CPHI Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $984K-19.8% | $1.2M+62.1% | $756K-26.3% | $1.0M-9.7% | $1.1M+0.2% | $1.1M+3.1% | $1.1M+18.9% | $925K |
| Cost of Revenue | $698K-35.1% | $1.1M+31.8% | $816K-26.7% | $1.1M-12.5% | $1.3M-1.7% | $1.3M-20.1% | $1.6M-16.5% | $1.9M |
| Gross Profit | $285K+89.3% | $151K+352.7% | -$60K+31.4% | -$87K+36.1% | -$136K+15.3% | -$161K+69.1% | -$520K+48.8% | -$1.0M |
| R&D Expenses | $84K-55.9% | $190K+371.3% | $40K+92.4% | $21K-29.2% | $30K+5309.0% | $547-99.4% | $88K-46.7% | $164K |
| SG&A Expenses | $1.2M+13.7% | $1.1M+153.9% | $425K-3.6% | $441K-13.1% | $507K-41.0% | $859K+149.1% | $345K+275.6% | $92K |
| Operating Income | -$1.1M+6.9% | -$1.2M-91.1% | -$628K+3.7% | -$652K+14.0% | -$759K+36.6% | -$1.2M-10.2% | -$1.1M+22.0% | -$1.4M |
| Interest Expense | $9K+31.5% | $7K+1.6% | $7K+0.3% | $7K-0.1% | $7K-0.2% | $7K-0.6% | $7K-0.1% | $7K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$1.1M+6.5% | -$1.2M-87.6% | -$651K-23.3% | -$528K+32.7% | -$786K+35.8% | -$1.2M-9.5% | -$1.1M+22.3% | -$1.4M |
| EPS (Diluted) | $-0.04 | N/A | $-0.17-6.3% | $-0.16 | $-0.24 | N/A | $-0.65+27.0% | $-0.89 |
CPHI Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $45.1M+45.6% | $31.0M+96.1% | $15.8M+14.8% | $13.8M-3.2% | $14.2M-4.5% | $14.9M+10.6% | $13.5M-5.6% | $14.3M |
| Current Assets | $2.0M-14.6% | $2.3M+0.7% | $2.3M-13.8% | $2.7M-5.3% | $2.9M-12.8% | $3.3M-12.5% | $3.7M-5.9% | $4.0M |
| Cash & Equivalents | $168K-51.2% | $345K+29.0% | $268K-55.4% | $600K+50.0% | $400K-36.2% | $627K-10.4% | $700K-5.3% | $739K |
| Inventory | $1.5M-7.6% | $1.6M-1.7% | $1.6M-1.7% | $1.7M-15.2% | $2.0M-12.7% | $2.3M-9.3% | $2.5M-11.4% | $2.8M |
| Accounts Receivable | $196K-18.7% | $241K+7.5% | $225K-16.4% | $269K-18.3% | $329K+41.7% | $232K-30.4% | $333K+30.8% | $255K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $8.1M-1.7% | $8.3M+10.3% | $7.5M+2.5% | $7.3M+0.8% | $7.2M+1.5% | $7.1M+2.9% | $6.9M+1.2% | $6.9M |
| Current Liabilities | $7.3M-1.8% | $7.4M+11.7% | $6.6M+26.1% | $5.3M+2.5% | $5.1M+2.1% | $5.0M+5.4% | $4.8M+1.0% | $4.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $37.0M+62.8% | $22.7M+173.5% | $8.3M+28.7% | $6.5M-7.3% | $7.0M-10.0% | $7.7M+18.7% | $6.5M-11.9% | $7.4M |
| Retained Earnings | -$48.4M-2.4% | -$47.2M-2.7% | -$46.0M-1.4% | -$45.3M-1.2% | -$44.8M-1.8% | -$44.0M-2.9% | -$42.8M-2.7% | -$41.7M |
CPHI Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$55K-136.4% | $152K+164.1% | -$237K-177.2% | $307K+516.6% | -$74K-124.7% | $299K+736.3% | -$47K+35.4% | -$73K |
| Capital Expenditures | $58K+12746.7% | $454-25.7% | $611+1040.0% | -$65-100.1% | $58K+198.4% | $20K+312.0% | -$9K | N/A |
| Free Cash Flow | -$114K-175.0% | $152K+163.8% | -$238K-177.4% | $307K+332.5% | -$132K-147.3% | $279K+597.1% | -$56K | N/A |
| Investing Cash Flow | -$58K-911.3% | -$6K+85.8% | -$41K-24.7% | -$33K+44.2% | -$58K+78.6% | -$273K-3059.3% | $9K | N/A |
| Financing Cash Flow | -$79K-9.3% | -$73K+40.6% | -$122K-445.6% | -$22K+70.8% | -$77K-41.4% | -$54K-894.0% | $7K-0.1% | $7K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CPHI Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 29.0%+16.7pp | 12.3%+20.2pp | -7.9%+0.6pp | -8.5%+3.5pp | -12.0%+2.2pp | -14.2%+33.1pp | -47.2%+62.6pp | -109.8% |
| Operating Margin | -113.6%-15.7pp | -97.9%-14.8pp | -83.1%-19.5pp | -63.6%+3.2pp | -66.8%+38.7pp | -105.5%-6.8pp | -98.7%+51.8pp | -150.4% |
| Net Margin | -116.2%-16.6pp | -99.7%-13.5pp | -86.2%-34.6pp | -51.5%+17.6pp | -69.1%+38.9pp | -108.0%-6.4pp | -101.6%+53.9pp | -155.5% |
| Return on Equity | -3.1%+2.3pp | -5.4%+2.5pp | -7.8%+0.3pp | -8.2%+3.1pp | -11.3%+4.5pp | -15.8%+1.3pp | -17.1%+2.3pp | -19.4% |
| Return on Assets | -2.5%+1.4pp | -3.9%+0.2pp | -4.1%-0.3pp | -3.8%+1.7pp | -5.5%+2.7pp | -8.2%+0.1pp | -8.3%+1.8pp | -10.1% |
| Current Ratio | 0.28-0.0 | 0.32-0.0 | 0.35-0.2 | 0.51-0.0 | 0.56-0.1 | 0.65-0.1 | 0.79-0.1 | 0.84 |
| Debt-to-Equity | 0.22-0.1 | 0.36-0.5 | 0.90-0.2 | 1.13+0.1 | 1.04+0.1 | 0.92-0.1 | 1.06+0.1 | 0.93 |
| FCF Margin | -11.6%-23.9pp | 12.4%+43.8pp | -31.4%-61.3pp | 29.9%+41.5pp | -11.6%-36.2pp | 24.6%+29.7pp | -5.1% | N/A |
Note: The current ratio is below 1.0 (0.32), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is China Pharma's annual revenue?
China Pharma (CPHI) reported $4.1M in total revenue for fiscal year 2025. This represents a -8.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is China Pharma's revenue growing?
China Pharma (CPHI) revenue declined by 8.5% year-over-year, from $4.5M to $4.1M in fiscal year 2025.
Is China Pharma profitable?
No, China Pharma (CPHI) reported a net income of -$3.2M in fiscal year 2025, with a net profit margin of -76.9%.
What is China Pharma's EBITDA?
China Pharma (CPHI) had EBITDA of -$1.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is China Pharma's gross margin?
China Pharma (CPHI) had a gross margin of -3.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is China Pharma's operating margin?
China Pharma (CPHI) had an operating margin of -78.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is China Pharma's net profit margin?
China Pharma (CPHI) had a net profit margin of -76.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is China Pharma's return on equity (ROE)?
China Pharma (CPHI) has a return on equity of -14.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is China Pharma's free cash flow?
China Pharma (CPHI) generated $89K in free cash flow during fiscal year 2025. This represents a 120.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is China Pharma's operating cash flow?
China Pharma (CPHI) generated $148K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are China Pharma's total assets?
China Pharma (CPHI) had $31.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are China Pharma's capital expenditures?
China Pharma (CPHI) invested $59K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does China Pharma spend on research and development?
China Pharma (CPHI) invested $281K in research and development during fiscal year 2025.
What is China Pharma's current ratio?
China Pharma (CPHI) had a current ratio of 0.32 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is China Pharma's debt-to-equity ratio?
China Pharma (CPHI) had a debt-to-equity ratio of 0.36 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is China Pharma's return on assets (ROA)?
China Pharma (CPHI) had a return on assets of -10.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is China Pharma's Altman Z-Score?
China Pharma (CPHI) has an Altman Z-Score of -0.86, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is China Pharma's Piotroski F-Score?
China Pharma (CPHI) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are China Pharma's earnings high quality?
China Pharma (CPHI) has an earnings quality ratio of -0.05x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can China Pharma cover its interest payments?
China Pharma (CPHI) has an interest coverage ratio of -118.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is China Pharma?
China Pharma (CPHI) scores 44 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.